Intech Biopharm Corporation (TPEX:6461)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
16.95
-0.15 (-0.88%)
May 8, 2026, 1:23 PM CST
Market Cap3.02B +20.8%
Revenue (ttm)107.53M +170.3%
Net Income-389.03M
EPS-2.57
Shares Out178.41M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60,036
Average Volume261,180
Open17.30
Previous Close17.10
Day's Range16.80 - 17.30
52-Week Range14.10 - 26.25
Beta0.22
RSI34.59
Earnings DateMay 12, 2026

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 90
Stock Exchange Taipei Exchange
Ticker Symbol 6461
Full Company Profile

Financial Performance

In 2025, Intech Biopharm's revenue was 107.53 million, an increase of 170.31% compared to the previous year's 39.78 million. Losses were -389.03 million, 5.66% more than in 2024.

Financial Statements